Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis.

Saved in:
Bibliographic Details
Title: Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis.
Authors: Umbleja T; Center for Biostatistics in AIDS Research, Harvard T H Chan School of Public Health, Boston, MA, USA., Zafar MU; Atherothrombosis Research Unit, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA., McCallum S; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Gattu AK; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Zanni MV; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Bloomfield GS; Department of Medicine, Duke Global Health Institute, and Duke Clinical Research Institute, Duke University, Durham, NC, USA., Malvestutto CD; Division of Infectious Diseases, Ohio State University Medical Center, Columbus, OH, USA., Fichtenbaum CJ; Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, OH, USA., Currier JS; Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Sponseller CA; Kowa Pharmaceuticals America, Montgomery, AL, USA., Diggs MR; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Chu SM; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Lu AB; Center for Biostatistics in AIDS Research, Harvard T H Chan School of Public Health, Boston, MA, USA., Glesby MJ; Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY, USA., Stapleton JT; Department of Medicine, The University of Iowa and The Iowa City Veterans Affairs Health Care System, Iowa City, IA, USA., Frank M; Division of Infectious Diseases, Medical College of Wisconsin, Milwaukee, WI, USA., Nguyen KL; Division of Cardiology, David Geffen School of Medicine at UCLA and VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA., Bender Ignacio RA; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA; Vaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, WA, USA., Han WM; HIV-NAT, Thai Red Cross AIDS and Infectious Diseases Research Centre, Bangkok, Thailand; The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia., Douglas PS; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA., Aberg JA; Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Ribaudo HJ; Center for Biostatistics in AIDS Research, Harvard T H Chan School of Public Health, Boston, MA, USA., Grinspoon SK; Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: sgrinspoon@mgh.harvard.edu.
Source: The lancet. HIV [Lancet HIV] 2026 May; Vol. 13 (5), pp. e316-e326. Date of Electronic Publication: 2026 Apr 02.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III
Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101645355 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3018 (Electronic) Linking ISSN: 23523018 NLM ISO Abbreviation: Lancet HIV Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2352-3018
DOI:10.1016/S2352-3018(26)00031-7